Following the recent announcement that Avion Pharmaceuticals has entered into a licence to pay up to $25m to develop (through the second phase III trial) and commercialise its major drug Lupuzor ™, ImmuPharma presents a very different opportunity compared to even a few weeks ago.
09 Dec 2019
ImmuPharma Quick Reference Sheet following new Lupuzor licence
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ImmuPharma Quick Reference Sheet following new Lupuzor licence
ImmuPharma plc (IMM:LON) | 2.1 0 1.4% | Mkt Cap: 8.93m
- Published:
09 Dec 2019 -
Author:
Oliver Juggins -
Pages:
2
Following the recent announcement that Avion Pharmaceuticals has entered into a licence to pay up to $25m to develop (through the second phase III trial) and commercialise its major drug Lupuzor ™, ImmuPharma presents a very different opportunity compared to even a few weeks ago.